1
|
Nair A, Greeny A, Nandan A, Sah RK, Jose A, Dyawanapelly S, Junnuthula V, K V A, Sadanandan P. Advanced drug delivery and therapeutic strategies for tuberculosis treatment. J Nanobiotechnology 2023; 21:414. [PMID: 37946240 PMCID: PMC10634178 DOI: 10.1186/s12951-023-02156-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Accepted: 10/11/2023] [Indexed: 11/12/2023] Open
Abstract
Tuberculosis (TB) remains a significant global health challenge, necessitating innovative approaches for effective treatment. Conventional TB therapy encounters several limitations, including extended treatment duration, drug resistance, patient noncompliance, poor bioavailability, and suboptimal targeting. Advanced drug delivery strategies have emerged as a promising approach to address these challenges. They have the potential to enhance therapeutic outcomes and improve TB patient compliance by providing benefits such as multiple drug encapsulation, sustained release, targeted delivery, reduced dosing frequency, and minimal side effects. This review examines the current landscape of drug delivery strategies for effective TB management, specifically highlighting lipid nanoparticles, polymer nanoparticles, inorganic nanoparticles, emulsion-based systems, carbon nanotubes, graphene, and hydrogels as promising approaches. Furthermore, emerging therapeutic strategies like targeted therapy, long-acting therapeutics, extrapulmonary therapy, phototherapy, and immunotherapy are emphasized. The review also discusses the future trajectory and challenges of developing drug delivery systems for TB. In conclusion, nanomedicine has made substantial progress in addressing the challenges posed by conventional TB drugs. Moreover, by harnessing the unique targeting abilities, extended duration of action, and specificity of advanced therapeutics, innovative solutions are offered that have the potential to revolutionize TB therapy, thereby enhancing treatment outcomes and patient compliance.
Collapse
Affiliation(s)
- Ayushi Nair
- Department of Pharmaceutics, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, 682 041, Kerala, India
| | - Alosh Greeny
- Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, 682 041, Kerala, India
| | - Amritasree Nandan
- Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, 682 041, Kerala, India
| | - Ranjay Kumar Sah
- Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, 682 041, Kerala, India
| | - Anju Jose
- Department of Pharmacology, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, 682 041, Kerala, India
| | - Sathish Dyawanapelly
- Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, 400019, India
| | | | - Athira K V
- Department of Pharmacology, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, 682 041, Kerala, India.
| | - Prashant Sadanandan
- Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, 682 041, Kerala, India.
| |
Collapse
|
2
|
Sheikh BA, Bhat BA, Alshehri B, Mir RA, Mir WR, Parry ZA, Mir MA. Nano-Drug Delivery Systems: Possible End to the Rising Threats of Tuberculosis. J Biomed Nanotechnol 2021; 17:2298-2318. [PMID: 34974855 DOI: 10.1166/jbn.2021.3201] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Tuberculosis (TB) is still one of the deadliest disease across the globe caused by Mycobacterium tuberculosis (Mtb). Mtb invades host macrophages and other immune cells, modifies their lysosome trafficking proteins, prevents phagolysosomes formation, and inhibits the TNF receptor-dependent apoptosis in macrophages and monocytes. Tuberculosis (TB) killed 1.4 million people worldwide in the year 2019. Despite the advancements in tuberculosis (TB) treatments, multidrugresistant tuberculosis (MDR-TB) remains a severe threat to human health. The complications are further compounded by the emergence of MDR/XDR strains and the failure of conventional drug regimens to eradicate the resistant bacterial strains. Thus, new therapeutic approaches aim to ensure cure without relapse, to prevent the occurrence of deaths and emergence of drug-resistant strains. In this context, this review article summarises the essential nanotechnology-related research outcomes in the treatment of tuberculosis (TB), including drug-susceptible and drug-resistant strains of Mtb. The novel anti-tuberculosis drug delivery systems are also being detailed. This article highlights recent advances in tuberculosis (TB) treatments, including the use of novel drug delivery technologies such as solid lipid nanoparticles, liposomes, polymeric micelles, nano-suspensions, nano-emulsion, niosomes, liposomes, polymeric nanoparticles and microparticles for the delivery of anti-TB drugs and hence eradication and control of both drug-susceptible as well as drug-resistant strains of Mtb.
Collapse
Affiliation(s)
- Bashir A Sheikh
- Department of Bio-Resources, School of Biological Sciences, University of Kashmir, Srinagar 190006, J&K, India
| | - Basharat A Bhat
- Department of Bio-Resources, School of Biological Sciences, University of Kashmir, Srinagar 190006, J&K, India
| | - Bader Alshehri
- Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University KSA, Almajmaah, 11952, Saudi Arabia
| | - Rakeeb A Mir
- Department of Biotechnology, School of Biosciences and Biotechnology, BGSB University, Rajouri 185234, J&K, India
| | - Wajahat R Mir
- Department of Bio-Resources, School of Biological Sciences, University of Kashmir, Srinagar 190006, J&K, India
| | - Zahoor A Parry
- Clinical Microbiology PK/PD/Laboratory, Indian Institute of Integrated Medicine (IIIM)-Srinagar 190005, J&K, India
| | - Manzoor A Mir
- Department of Bio-Resources, School of Biological Sciences, University of Kashmir, Srinagar 190006, J&K, India
| |
Collapse
|
3
|
Truzzi E, Nascimento TL, Iannuccelli V, Costantino L, Lima EM, Leo E, Siligardi C, Gualtieri ML, Maretti E. In Vivo Biodistribution of Respirable Solid Lipid Nanoparticles Surface-Decorated with a Mannose-Based Surfactant: A Promising Tool for Pulmonary Tuberculosis Treatment? NANOMATERIALS 2020; 10:nano10030568. [PMID: 32245153 PMCID: PMC7153707 DOI: 10.3390/nano10030568] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Revised: 03/18/2020] [Accepted: 03/19/2020] [Indexed: 12/21/2022]
Abstract
The active targeting to alveolar macrophages (AM) is an attractive strategy to improve the therapeutic efficacy of ‘old’ drugs currently used in clinical practice for the treatment of pulmonary tuberculosis. Previous studies highlighted the ability of respirable solid lipid nanoparticle assemblies (SLNas), loaded with rifampicin (RIF) and functionalized with a novel synthesized mannose-based surfactant (MS), both alone and in a blend with sodium taurocholate, to efficiently target the AM via mannose receptor-mediated mechanism. Here, we present the in vivo biodistribution of these mannosylated SLNas, in comparison with the behavior of both non-functionalized SLNas and bare RIF. SLNas biodistribution was assessed, after intratracheal instillation in mice, by whole-body real-time fluorescence imaging in living animals and RIF quantification in excised organs and plasma. Additionally, SLNas cell uptake was determined by using fluorescence microscopy on AM from bronchoalveolar lavage fluid and alveolar epithelium from lung dissections. Finally, histopathological evaluation was performed on lungs 24 h after administration. SLNas functionalized with MS alone generated the highest retention in lungs associated with a poor spreading in extra-pulmonary regions. This effect could be probably due to a greater AM phagocytosis with respect to SLNas devoid of mannose on their surface. The results obtained pointed out the unique ability of the nanoparticle surface decoration to provide a potential more efficient treatment restricted to the lungs where the primary tuberculosis infection is located.
Collapse
Affiliation(s)
- Eleonora Truzzi
- Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy; (E.T.); (V.I.); (L.C.); (E.L.)
| | - Thais Leite Nascimento
- Laboratory of Pharmaceutical Technology, Federal University of Goiás, Goiânia, Goiás 74605-170, Brazil; (T.L.N.); (E.M.L.)
| | - Valentina Iannuccelli
- Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy; (E.T.); (V.I.); (L.C.); (E.L.)
| | - Luca Costantino
- Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy; (E.T.); (V.I.); (L.C.); (E.L.)
| | - Eliana Martins Lima
- Laboratory of Pharmaceutical Technology, Federal University of Goiás, Goiânia, Goiás 74605-170, Brazil; (T.L.N.); (E.M.L.)
| | - Eliana Leo
- Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy; (E.T.); (V.I.); (L.C.); (E.L.)
| | - Cristina Siligardi
- Department of Engineering “Enzo Ferrari”, University of Modena and Reggio Emilia, 41125 Modena, Italy; (C.S.); (M.L.G.)
| | | | - Eleonora Maretti
- Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy; (E.T.); (V.I.); (L.C.); (E.L.)
- Correspondence:
| |
Collapse
|
4
|
De Maio F, Palmieri V, De Spirito M, Delogu G, Papi M. Carbon nanomaterials: a new way against tuberculosis. Expert Rev Med Devices 2019; 16:863-875. [PMID: 31550943 DOI: 10.1080/17434440.2019.1671820] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Introduction: Tuberculosis (TB) remains one of the most alarming worldwide infectious diseases primarily in low-income countries, where the infection shows a higher and unvaried prevalence. In the last years, the emergence and spread of Mycobacterium tuberculosis (Mtb) strains resistant to first-line anti-TB drugs are the cause of major concern and prompted the implementation of new treatments, including the development of new drugs and the repurposing of old ones. Areas covered: In this review, we discuss solutions against TB based on nanomaterials (NMTs), alone or combined with current anti-TB drugs. We will summarize drug delivery platforms tested in in vivo or in vitro models and their activity against mycobacteria. We will describe how the new nanotechnologies based on carbon nanomaterials, like carbon nanotubes and graphene oxide are now facing the panorama of the medical fight against TB. Expert opinion: We foresee that in the next decade carbon nanomaterials will be at the forefront in fighting emerging antibiotic-resistant Mtb strains by shortening treatment periods, reducing adverse effects and mitigating antibiotic use. However, toxicity and biodegradation studies should be done prior to the clinical translation of carbon nanomaterials.
Collapse
Affiliation(s)
- Flavio De Maio
- Fondazione Policlinico Universitario A. Gemelli, IRCCS , Roma , Italy.,Institute of Microbiology, Università Cattolica del Sacro Cuore , Roma , Italy
| | - Valentina Palmieri
- Fondazione Policlinico Universitario A. Gemelli, IRCCS , Roma , Italy.,Institute of Physics, Università Cattolica del Sacro Cuore , Roma , Italy
| | - Marco De Spirito
- Fondazione Policlinico Universitario A. Gemelli, IRCCS , Roma , Italy.,Institute of Physics, Università Cattolica del Sacro Cuore , Roma , Italy
| | - Giovanni Delogu
- Fondazione Policlinico Universitario A. Gemelli, IRCCS , Roma , Italy.,Institute of Microbiology, Università Cattolica del Sacro Cuore , Roma , Italy
| | - Massimiliano Papi
- Fondazione Policlinico Universitario A. Gemelli, IRCCS , Roma , Italy.,Institute of Physics, Università Cattolica del Sacro Cuore , Roma , Italy
| |
Collapse
|
5
|
Churilov L, Korzhikov-Vlakh V, Sinitsyna E, Polyakov D, Darashkevich O, Poida M, Platonova G, Vinogradova T, Utekhin V, Zabolotnykh N, Zinserling V, Yablonsky P, Urtti A, Tennikova T. Enhanced Delivery of 4-Thioureidoiminomethylpyridinium Perchlorate in Tuberculosis Models with IgG Functionalized Poly(Lactic Acid)-Based Particles. Pharmaceutics 2018; 11:E2. [PMID: 30577686 PMCID: PMC6359407 DOI: 10.3390/pharmaceutics11010002] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Revised: 12/11/2018] [Accepted: 12/18/2018] [Indexed: 02/07/2023] Open
Abstract
The compound 4-thioureidoiminomethylpyridinium perchlorate (perchlozone©) is a novel anti-tuberculosis drug that is active in multiple drug resistance cases, but the compound is hepatotoxic. To decrease the systemic load and to achieve targeting, we encapsulated the drug into poly(lactic acid)-based micro- (1100 nm) and nanoparticles (170 nm) that were modified with single-chain camel immunoglobulin G (IgG) for targeting. Both micro- and nanoparticles formed stable suspensions in saline solution at particle concentrations of 10⁻50 mg/mL. The formulations were injected intraperitoneally and intravenously into the mice with experimental tuberculosis. The survival of control animals was compared to that of mice which were treated with daily oral drug solution, single intraperitoneal administration of drug-loaded particles, and those treated both intravenously and intraperitoneally by drug-loaded particles modified with polyclonal camel IgGs. The distribution of particles in the organs of mice was analyzed with immunofluorescence and liquid chromatography/mass spectrometry. Morphological changes related to tuberculosis and drug toxicity were registered. Phagocytic macrophages internalized particles and transported them to the foci of tuberculosis in inner organs. Nanoparticle-based drug formulations, especially those with IgG, resulted in better survival and lower degree of lung manifestations than the other modes of treatment.
Collapse
Affiliation(s)
- Leonid Churilov
- Faculty of Medicine, Saint Petersburg State University, 7/9 Universitetskaya Embankment, 199034 St. Petersburg, Russia.
| | - Viktor Korzhikov-Vlakh
- Institute of Chemistry, Saint Petersburg State University, 7/9 Universitetskaya Embankment, 199034 St. Petersburg, Russia.
| | - Ekaterina Sinitsyna
- Institute of Chemistry, Saint Petersburg State University, 7/9 Universitetskaya Embankment, 199034 St. Petersburg, Russia.
- Institute of Macromolecular Compounds, Russian Academy of Sciences, Bolshoi pr. V.O. 31, 199004 St. Petersburg, Russia.
| | - Dmitry Polyakov
- Institute of Chemistry, Saint Petersburg State University, 7/9 Universitetskaya Embankment, 199034 St. Petersburg, Russia.
| | - Oleg Darashkevich
- Republican Center for Innovative and Technical Creativity, Slavinskogo str. 12, 220086 Minsk, Belarus.
| | - Mikhail Poida
- Faculty of Medicine, Saint Petersburg State University, 7/9 Universitetskaya Embankment, 199034 St. Petersburg, Russia.
| | - Galina Platonova
- Institute of Macromolecular Compounds, Russian Academy of Sciences, Bolshoi pr. V.O. 31, 199004 St. Petersburg, Russia.
| | - Tatiana Vinogradova
- St. Petersburg Research Institute of Phthisiopulmonology, Polytechnical str. 32, 194064 St. Petersburg, Russia.
| | - Vladimir Utekhin
- Faculty of Medicine, Saint Petersburg State University, 7/9 Universitetskaya Embankment, 199034 St. Petersburg, Russia.
| | - Natalia Zabolotnykh
- St. Petersburg Research Institute of Phthisiopulmonology, Polytechnical str. 32, 194064 St. Petersburg, Russia.
| | - Vsevolod Zinserling
- Faculty of Medicine, Saint Petersburg State University, 7/9 Universitetskaya Embankment, 199034 St. Petersburg, Russia.
| | - Peter Yablonsky
- Faculty of Medicine, Saint Petersburg State University, 7/9 Universitetskaya Embankment, 199034 St. Petersburg, Russia.
- St. Petersburg Research Institute of Phthisiopulmonology, Polytechnical str. 32, 194064 St. Petersburg, Russia.
| | - Arto Urtti
- Institute of Chemistry, Saint Petersburg State University, 7/9 Universitetskaya Embankment, 199034 St. Petersburg, Russia.
| | - Tatiana Tennikova
- Institute of Chemistry, Saint Petersburg State University, 7/9 Universitetskaya Embankment, 199034 St. Petersburg, Russia.
| |
Collapse
|
6
|
Carbó-Laso E, Sanz-Ruiz P, del Real-Romero J, Ballesteros-Iglesias Y, Paz-Jiménez E, Arán-Ais F, Sánchez-Navarro M, Pérez-Limiñana M, López-Torres I, Vaquero-Martín J. New method for antibiotic release from bone cement (polymethylmethacrylate): Redefining boundaries. Rev Esp Cir Ortop Traumatol (Engl Ed) 2018. [DOI: 10.1016/j.recote.2017.12.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
7
|
Carbó-Laso E, Sanz-Ruiz P, Del Real-Romero JC, Ballesteros-Iglesias Y, Paz-Jiménez E, Arán-Ais F, Sánchez-Navarro M, Pérez-Limiñana MA, López-Torres I, Vaquero-Martín J. New method for antibiotic release from bone cement (polymethylmethacrylate): Redefining boundaries. Rev Esp Cir Ortop Traumatol (Engl Ed) 2017; 62:86-92. [PMID: 29157990 DOI: 10.1016/j.recot.2017.08.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Revised: 05/11/2017] [Accepted: 08/30/2017] [Indexed: 01/25/2023] Open
Abstract
INTRODUCTION The increasing antimicrobial resistance is promoting the addition of antibiotics with high antistaphylococcal activity to polymethylmethacrylate (PMMA), for use in cement spacers in periprosthetic joint infection. Linezolid and levofloxacin have already been used in in-vitro studies, however, rifampicin has been shown to have a deleterious effect on the mechanical properties of PMMA, because it inhibits PMMA polymerization. The objective of our study was to isolate the rifampicin during the polymerization process using microencapsulation techniques, in order to obtain a PMMA suitable for manufacturing bone cement spacers. MATERIAL AND METHOD Microcapsules of rifampicin were synthesized with alginate and PHBV, using Rifaldin®. The concentration levels of rifampicin were studied by UV-visible spectrophotometry. Compression, hardness and setting time tests were performed with CMW®1 cement samples alone, with non-encapsulated rifampicin and with alginate or PHBV microcapsules. RESULTS The production yield, efficiency and microencapsulation yield were greater with alginate (P = .0001). The cement with microcapsules demonstrated greater resistance to compression than the cement with rifampicin (91.26±5.13, 91.35±6.29 and 74.04±3.57 MPa in alginate, PHBV and rifampicin, respectively) (P = .0001). The setting time reduced, and the hardness curve of the cement with alginate microcapsules was similar to that of the control. DISCUSSION AND CONCLUSIONS Microencapsulation with alginate is an appropriate technique for introducing rifampicin into PMMA, preserving compression properties and setting time. This could allow intraoperative manufacturing of bone cement spacers that release rifampicin for the treatment of periprosthetic joint infection.
Collapse
Affiliation(s)
- E Carbó-Laso
- Servicio de Cirugía Ortopédica y Traumatología, Hospital General Universitario Gregorio Marañón, Madrid, España.
| | - P Sanz-Ruiz
- Servicio de Cirugía Ortopédica y Traumatología, Hospital General Universitario Gregorio Marañón, Madrid, España; Departamento de Cirugía, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, España
| | - J C Del Real-Romero
- Departamento de Ingeniería Mecánica, Instituto de Investigación en Tecnología, Universidad Pontificia Comillas, Madrid, España
| | - Y Ballesteros-Iglesias
- Departamento de Ingeniería Mecánica, Instituto de Investigación en Tecnología, Universidad Pontificia Comillas, Madrid, España
| | - E Paz-Jiménez
- Departamento de Ingeniería Mecánica, Instituto de Investigación en Tecnología, Universidad Pontificia Comillas, Madrid, España
| | - F Arán-Ais
- Departamento de Microencapsulación y Nanotecnología, Instituto Tecnológico del Calzado y Conexas (INESCOP), Elda, Alicante, España
| | - M Sánchez-Navarro
- Departamento de Microencapsulación y Nanotecnología, Instituto Tecnológico del Calzado y Conexas (INESCOP), Elda, Alicante, España
| | - M A Pérez-Limiñana
- Departamento de Microencapsulación y Nanotecnología, Instituto Tecnológico del Calzado y Conexas (INESCOP), Elda, Alicante, España
| | - I López-Torres
- Servicio de Cirugía Ortopédica y Traumatología, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - J Vaquero-Martín
- Servicio de Cirugía Ortopédica y Traumatología, Hospital General Universitario Gregorio Marañón, Madrid, España; Departamento de Cirugía, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, España
| |
Collapse
|
8
|
Maretti E, Costantino L, Rustichelli C, Leo E, Croce MA, Buttini F, Truzzi E, Iannuccelli V. Surface engineering of Solid Lipid Nanoparticle assemblies by methyl α- d -mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy. Int J Pharm 2017. [DOI: 10.1016/j.ijpharm.2017.06.045] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
9
|
Maretti E, Rustichelli C, Romagnoli M, Balducci AG, Buttini F, Sacchetti F, Leo E, Iannuccelli V. Solid Lipid Nanoparticle assemblies (SLNas) for an anti-TB inhalation treatmentA Design of Experiments approach to investigate the influence of pre-freezing conditions on the powder respirability. Int J Pharm 2016; 511:669-679. [DOI: 10.1016/j.ijpharm.2016.07.062] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2016] [Revised: 07/25/2016] [Accepted: 07/26/2016] [Indexed: 11/16/2022]
|
10
|
Singh J, Garg T, Rath G, Goyal AK. Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis – a critical review. Drug Deliv 2015; 23:1676-98. [DOI: 10.3109/10717544.2015.1074765] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Bushmakina IM, Martynova MA, Knyazeva EV. XXI Century: How Our Notions About Liposomal Drugs Have Been Transformed. Pharm Chem J 2015. [DOI: 10.1007/s11094-015-1232-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
12
|
Staudinger T, Redl B, Glasgow BJ. Antibacterial activity of rifamycins for M. smegmatis with comparison of oxidation and binding to tear lipocalin. BIOCHIMICA ET BIOPHYSICA ACTA 2014; 1844:750-8. [PMID: 24530503 PMCID: PMC3992280 DOI: 10.1016/j.bbapap.2014.02.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/26/2013] [Revised: 01/28/2014] [Accepted: 02/03/2014] [Indexed: 11/19/2022]
Abstract
A mutant of Mycobacterium smegmatis is a potential class I model substitute for Mycobacterium tuberculosis. Because not all of the rifamycins have been tested in this organism, we determined bactericidal profiles for the 6 major rifamycin derivatives. The profiles closely mirrored those established for M. tuberculosis. Rifalazil was confirmed to be the most potent rifamycin. Because the tuberculous granuloma presents a harshly oxidizing environment we explored the effects of oxidation on rifamycins. Mass spectrometry confirmed that three of the six major rifamycins showed autoxidation in the presence of trace metals. Oxidation could be monitored by distinctive changes including isosbestic points in the ultraviolet-visible spectrum. Oxidation of rifamycins abrogated anti-mycobacterial activity in M. smegmatis. Protection from autoxidation was conferred by binding susceptible rifamycins to tear lipocalin, a promiscuous lipophilic protein. Rifalazil was not susceptible to autoxidation but was insoluble in aqueous solution. Solubility was enhanced when complexed to tear lipocalin and was accompanied by a spectral red shift. The positive solvatochromism was consistent with robust molecular interaction and binding. Other rifamycins also formed a complex with lipocalin, albeit to a lesser extent. Protection from oxidation and enhancement of solubility with protein binding may have implications for delivery of select rifamycin derivatives.
Collapse
Affiliation(s)
- Tamara Staudinger
- Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, 100 Stein Plaza, Rm. B-279, Los Angeles, CA 90095, USA; Department of Pathology and Laboratory Medicine, Jules Stein Eye Institute, University of California, Los Angeles, 100 Stein Plaza, Rm. B-279, Los Angeles, CA 90095, USA; Division of Molecular Biology, Biocenter, Innsbruck Medical University, Innrain 80-82, A-6020 Innsbruck, Austria
| | - Bernhard Redl
- Division of Molecular Biology, Biocenter, Innsbruck Medical University, Innrain 80-82, A-6020 Innsbruck, Austria
| | - Ben J Glasgow
- Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, 100 Stein Plaza, Rm. B-279, Los Angeles, CA 90095, USA; Department of Pathology and Laboratory Medicine, Jules Stein Eye Institute, University of California, Los Angeles, 100 Stein Plaza, Rm. B-279, Los Angeles, CA 90095, USA.
| |
Collapse
|
13
|
Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis. Int J Pharm 2014; 462:74-82. [DOI: 10.1016/j.ijpharm.2013.12.034] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2013] [Revised: 12/13/2013] [Accepted: 12/17/2013] [Indexed: 11/21/2022]
|
14
|
Niu C, Wang Z, Zuo G, Krupka TM, Ran H, Zhang P, Li P, Chen Y, Chen H, Zheng Y. Poly(Lactide-co-glycolide) ultrasonographic microbubbles carrying Sudan black for preoperative and intraoperative localization of lymph nodes. Clin Breast Cancer 2012; 12:199-206. [PMID: 22402214 DOI: 10.1016/j.clbc.2012.01.005] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2011] [Revised: 11/24/2011] [Accepted: 01/13/2012] [Indexed: 01/31/2023]
Abstract
Lymph node (LN) examination plays a critical role in the staging and treatment of several kinds of cancer such as lesions of the breast. However current strategies have limitations. This study aimed to develop a novel imaging agent, a polymeric ultrasonographic contrast agent carrying Sudan black (SB), for ultrasonographic imaging of the regional LNs before surgery and to directly localize the LNs during surgery. The poly(lactide-co-glycolide) (PLGA) ultrasonographic microbubbles carrying Sudan black B (SB) (SB-PLGA microbubbles) were prepared by the double emulsion method. The SB-PLGA microbubbles had a diameter of 1.5 ± 0.5 μm and the SB encapsulation efficiency was (86.2 ± 1.56%). Results from MTT assays suggested that these bubbles have little cytotoxicity to mouse macrophages after incubation. Confocal laser scanning microscopy showed that the PLGA microbubbles carrying the fluorescent dye rhodamine 6G were taken up by macrophages after 2-hour incubation. In addition, these SB-PLGA microbubbles were able to enhance ultrasonographic contrast of 12 popliteal LNs of 6 rabbits. Furthermore, the LNs were easily identifiable by the naked eye during surgery because of the blue color of the SB-PLGA microbubbles inside the LNs. By cryosectioning and hematoxylin and eosin (H&E) staining of LN tissue, our results showed that these SB-PLGA microbubbles were internalized inside the macrophages of the LNs. To conclude, the SB-PLGA microbubbles could be a suitable imaging agent for preoperative and intraoperative localization of LNs as well as for a preoperative ultrasonographically guided core needle biopsy of suspicious sentinel lymph nodes (SLNs) in cancer patients, hence enhancing treatment outcome.
Collapse
Affiliation(s)
- Chengcheng Niu
- Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Goreva AV, Shishatskaya EI, Volova TG, Sinskey AJ. Characterization of polymeric microparticles based on resorbable polyesters of oxyalkanoic acids as a platform for deposition and delivery of drugs. POLYMER SCIENCE SERIES A 2012. [DOI: 10.1134/s0965545x12020022] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
16
|
Disratthakit A, Doi N, Takenaga M, Ohta Y. Anti-tuberculosis activity and drug interaction with nevirapine of inhalable lipid microspheres containing rifampicin in murine model. J Microencapsul 2010; 27:365-71. [DOI: 10.3109/02652040903226507] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
17
|
Henning A, Hein S, Schneider M, Bur M, Lehr CM. Pulmonary drug delivery: medicines for inhalation. Handb Exp Pharmacol 2010:171-92. [PMID: 20217530 DOI: 10.1007/978-3-642-00477-3_6] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Mankind has inhaled substances for medical and other reasons for thousands of years, notably resulting in the cultural manifestations of tobacco and opium smoking. Over the course of time concepts of pulmonary application, including inhalation devices and drug formulations, have been and still are being continuously developed. State of the art instruments even allow for individualized drug application by adaptation of the inhalation procedure to the breathing pattern of the patient. Pulmonary drug delivery offers promising advantages in comparison to "classical" drug administration via the oral or transcutaneous routes, which is also reflected by an increasing interest and number of marketed products for inhalation therapy. However, the lungs' efficient clearance mechanisms still limit the benefit of many therapeutic concepts. In consequence the objective of current research and development in pulmonary drug delivery is to overcome and to control drug clearance from the intended target site. Here, several of the most auspicious future drug delivery concepts are presented and discussed in order to give the reader an insight into this emerging field of medicine.
Collapse
Affiliation(s)
- Andreas Henning
- Biopharmaceutics and Pharmaceutical Technology, Saarland University, 66123 Saarbrücken, Germany
| | | | | | | | | |
Collapse
|
18
|
|
19
|
Durán N, Alvarenga MA, Da Silva EC, Melo PS, Marcato PD. Microencapsulation of antibiotic rifampicin in poly(3-hydroxybutyrate-co-3-hydroxyvalerate). Arch Pharm Res 2008; 31:1509-16. [PMID: 19023549 DOI: 10.1007/s12272-001-2137-7] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2008] [Revised: 10/16/2008] [Accepted: 10/16/2008] [Indexed: 10/21/2022]
Abstract
The aim of this study was the preparation of microparticles containing rifampicin using a biodegradable polymer poly(3-hydroxybutyrate-co-3-hydroxyvalerate) for oral administration produced by a bacteria. The poly(3-hydroxybutyrate-co-3-hydroxyvalerate) microparticles with and without rifampicin were prepared by the emulsification and solvent evaporation method, in which chloroform and polyvinyl alcohol are used as the solvent and emulsifier, respectively. Microparticles were obtained within a size range of 20-60 microm by changing the initial poly(3-hydroxybutyrate-co-3-hydroxyvalerate), polyvinyl alcohol and rifampicin concentrations. An encapsulation efficiency value of 14% was obtained. The optimized total yield of 60% of the poly(3-hydroxybutyrate-co-3-hydroxyvalerate)/ rifampicin was obtained. A load of 0.035 mg/1 mg of PHBV was reached. Almost 90% of the drug loaded in the microparticles was released after 24 h. The size, encapsulation efficiency and ribampicin release of the microparticles varied as a function of the initial poly(3-hydroxybutyrate-co-3-hydroxyvalerate), polyvinyl alcohol and rifampicin concentrations. It was demonstrated that the microencapsulated rifampicin, although was not totally available in the medium, exhibited a similar inhibition value as free rifampicin at 24 h of incubation with S. aureus. Cytotoxicity assays demonstrated a reduction of the toxicity when rifampicin was microencapsulated in poly(3-hydroxybutyrate-co-3-hydroxyvalerate) while maintaining its antibacterial activity.
Collapse
Affiliation(s)
- N Durán
- Instituto de Quimica, Biological Chemistry Laboratory, Universidade Estadual de Campinas, C.P. 6154, Campinas CEP 13083-970, S.P, Brazil.
| | | | | | | | | |
Collapse
|